Prescription of psychotropic drugs in adolescent psychiatry wards in Finland

Nordic Journal of Psychiatry

Volumn 58, Issue 3, 2004, Pages 213-218

  Haapasalo Pesu, Kirsi Maria ^a   Erkolahti, Ritva ^b   Saarijärvi, Simo ^c   Aalberg, Veikko ^d  

^a Satakunta Hospital District   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Adolescent; Hospital; Inpatients; Psychotropic medication

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; PSYCHOTROPIC AGENT; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VITAMIN;

ADJUSTMENT DISORDER; ADOLESCENT; AGE; ALCOHOL ABUSE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD PSYCHIATRY; CONDUCT DISORDER; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DEVELOPMENTAL DISORDER; EMOTIONAL DISORDER; FEMALE; FINLAND; GENDER; HOSPITAL BED; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MENTAL DISEASE; MENTAL HOSPITAL; MOOD DISORDER; NEUROSIS; PERSONALITY DISORDER; PRESCRIPTION; PREVALENCE; PSYCHIATRIC DEPARTMENT; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIST; PSYCHOSIS; PSYCHOSOMATIC DISORDER; QUESTIONNAIRE; SAMPLING; SCHIZOPHRENIA; SOMATOFORM DISORDER; SUBSTANCE ABUSE;

ADOLESCENT; ADOLESCENT PSYCHIATRY; ADULT; DATA COLLECTION; DRUG UTILIZATION; FEMALE; FINLAND; HOSPITALS, DISTRICT; HOSPITALS, UNIVERSITY; HUMANS; MALE; MENTAL DISORDERS; PRESCRIPTIONS, DRUG; PSYCHIATRIC DEPARTMENT, HOSPITAL; PSYCHOTROPIC DRUGS;

EID: 3042852450     PISSN: 08039488     EISSN: None     Source Type: Journal    
DOI: 10.1080/08039480410006250     Document Type: Article

References (39)

1. Vitiello B, Bhatara VS, Jensen PS. Current Knowledge and Unmet Needs in Pediatric Psychopharmacology. J Am Acad Child Adolesc Psychiatry 1999;38(5):501-2.
2. Campbell M, Rapoport JL, Simpson GM. Antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999;38:537-55.
3. Spencer EK, Kafantaris V, Padron-Gayol MV, Rosenberg C, Campbell M. Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull 1992;28:183-6.
4. Pool D, Bloom W, Mielke DH, Roniger JJ Jr, Gallant DM. A controlled evaluation of Loxitane in seventy-five adolescent schizophrenia patients. Curr Ther Res Clin Exp 1976;19:99-104.
5. Ernst M, Malone RP, Rowan AB, George R, Gonzalez NM, Silva RR. Antipsychotics (neuroleptics). In: Werry JS, Aman MG, editors. Practitioner's guide to psychoactive drugs for children and adolescents, 2nd edition. New York: Plenum; 1998. p. 297-328.
6. Research Units on Pediatric Psychopharmacology Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-21.
7. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL. Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002;159:1337-46.
8. McAdam DB, Zarcone JR, Hellings J, Napolitano DA, Schroeder Sr. Effects of risperidone on aberrant behavior in persons with developmental disabilities: II. Social validity measures. Am J Ment Retard 2002;107:261-9.
9. Scahill L, McCracken J, McDougle CJ, Aman M, Arnold LE, Tierney E, et al. Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. J Child Adolesc Psychopharmacol 2001;11:377-88.
10. Sikich L, Hamer R, Malekpour A, Mendel R, White R, Bashford R, et al. Double-blind trial comparing risperidone, olanzapine and haloperidol in psychotic children and adolescents. Presented at AACAP Annual Meeting 2002, 15-20 May, in Philadelphia, Pennsylvania.
11. DelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment adolescent mania. J Am Acad Child Adolesc Psychiatry 2002;41:1216-23.
12. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, et al. Childhood onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53:1090-7.
13. Toren P, Laor N, Weizman A. Use of atypical neuroleptics in child and adolescent psychiatry. J Clin Psychiatry 1998;59:644-56.
14. Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: A meta-analysis. BMJ 1995;310:897-901.
15. Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and Adolescents. Cochrane Database Syst Rev 2002; 2:CD002317.
16. Emslie G, Rush JA, Weinberg AW, Kowatch RA, Hughes CW, Carmody T, et al. A double blind, randomized placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997;54:1031-7.
17. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, et al. Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002;41:1205-15.
18. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, et al. Efficacy of paroxetine in the treatment of adolescent major depression. A randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40:762-72.
19. Wagner KD, Robb AS, Findling R, Tiseo PJ. Citalopram treatment of pediatric depression: Results of a placebo-controlled trial. Presented at the Annual Meeting of The American College of Neuropsychopharmacology, Waikoloa Village, Hawaii; 2001.
20. Simeon J, Dinicola VF, Ferguson HB, Copping W. Adolescent depression: A placebo-controlled fluoxetine treatment study and follow-up. Prog Psychopharmacol Biol Psychiatry 1990;14:791-5.
21. Mandoki MW, Tapia MR, Tapia MA, Sumner GS, Parker JL. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull 1997;33:149-54.
22. Avci A, Diler RS, Kibar M, Sezgin F. Comparison of moclobemide and placebo in young adolescents with major disorder. Ann Med Sci 1999;8:31-40.
23. Kafarantis V. Treatment of bipolar disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 1995;34:732-41.
24. AACAP Official Action. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41 Suppl:26-49S.
25. National Agency for Medicines and Social Insurance Institution. Finnish statistics on Medicine 2001.
26. Olfson M, Marcus SC, Weissman MM, Jensen PS. National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 2002;41:514-21.
27. Erkolahti R, Piha J, Maling. Treatment practices in adolescent psychiatric inpatient care. Nord J Psychiatry 1998;52:519-26.
28. Laukkanen E, Hartikainen B, Luotoniemi M, Julma K, Aalberg V, Pylkkänen K. Nuorisopsykiatrian palvelut lisääntyneet, mutta eivät riitä kattamaan suurta tarvetta. Suom Lää käril 1999;32:3949-55. (In Finnish: Adolescent psychiatric services have increased but not enough to meet the increased demand.)
29. Milton JS, Arnold JC. Introduction to probability and statistics. New York: McGraw-Hill; 1990. p. 24, 296-7, 320-2.
30. Sourander A, Ellilä H, Välimäki M, Aronen E. Psychopharmacological treatment of child and adolescent psychiatric inpatients in Finland. J Child Adolesc Psychopharmacol 2002;12:147-55.
31. Safer DJ. Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990s. J Child Adolesc Psychopharmacol 1997;7:267-74.
32. Kaplan SL, Simms RM, Busner J. Prescribing practices of outpatient child psychiatrists. J Am Acad Child Adolesc Psychiatry 1994;33:35-44.
33. Gillberg C. Typical neuroleptics in child and adolescent psychiatry. J Eur Child Adolesc Psychiatry 2000;1:2-8.
34. Remschmidt H, Hennighausen K, Clement H-W, Heiser P, Schulz E. Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 2000;1:9-19.
35. AACAP Official Action. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2001;40 Suppl:4-23S.
36. Ryan ND, Bhatara VS, Perel JM. Mood stabilizers in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999;38:529-36.
37. Zwi M, Ramchandani P, Joughin C. Evidence and belief in ADHD. Informed decisions on stimulants must be based on studies with good methodology. BMJ 2000;321:975-6.
38. Riddle MA, Kastelic EA, Frosch E. Pediatric psycho-pharmacology. J Child Psychol Psychiatry 2001;42:73-90.
39. Vitiello B, Jensen PS. Developing clinical trials in children and adolescents. Psychopharmacol Bull 1995;31:75-81.